ArticleInvestigative ophthalmology & visual science2025
Melatonin Alleviates Age-Related Lacrimal Gland Dysfunction Via SIRT-1/NLRP3 Pathway.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ocular social jetlag: a driver of immune-metabolic dysfunction in dry eye disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: As a consequence of the natural aging process, the lacrimal glands may become dysfunctional. The present study aimed to investigate the potential role of melatonin (MLT) in the alleviation of age-related lacrimal gland dysfunction and to elucidate the underlying mechanism. Methods: In this study, lacrimal glands of 2-month-old, 18-month-old, and MLT intraperitoneally injected 18-month-old mice were obtained for immunofluorescence, immunohistochemistry experiments, and Western blotting to detect inflammatory factors and AQP5 expression, and for electron microscopy to detect mitochondrial structure and dense granules. Lacrimal glands from 18-month-old mice were taken for cell culture, and PCR and Western blotting were performed to detect the signaling pathways in which MLT acts. In addition, the human lacrimal gland explant cultures were performed to validate the role of MLT and the SIRT-1/NLRP3 signaling pathways. Results: In this study, we discovered that aging increased the inflammatory response, decreased secretory function, and led to mitochondrial dysregulation in lacrimal gland. Compared with 2-month-old mice, SIRT-1/3/6 gene transcript levels were significantly decreased in 18-month-old mice. MLT reduced inflammatory factors (IL-1β, IL-6, and TNF-α) and increased AQP5 expression via the SIRT-1/NLRP3 signaling pathway in aged lacrimal gland of human and mouse. Furthermore, MLT restored mitochondrial structure and increased dense granules in aged mouse lacrimal gland. In explants of human lacrimal gland, MLT relieved fibrosis. Conclusions: The present study demonstrated that MLT alleviates age-related lacrimal dysfunction in mice and humans via the SIRT-1/NLRP3 pathway. MLT alleviated the inflammatory response and the decline in the secretory function of the aged lacrimal gland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.